Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - caffeine 100mg (anhydrous); ergotamine tartrate 1mg;  ;   - tablet - 100 mg/1 mg - active: caffeine 100mg (anhydrous) ergotamine tartrate 1mg     excipient: iron oxide yellow magnesium stearate microcrystalline cellulose purified talc starch tartaric acid - treatment of acute attacks of migraine with or without aura in adults.

Yhdysvallat - englanti - NLM (National Library of Medicine)

kaiser foundation hospitals - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t) - ergotamine tartrate 1 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch health us, llc - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate 1 mg in 1 ml - d.h.e. 45 (dihydroergotamine mesylate) injection, usp is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp3a4 inhibitors (i.e., ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore, contraindicated (see warnings, cyp3a4 inhibitors ). d.h.e. 45 (dihydroergotamine mesylate) injection, usp should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm includi

Yhdysvallat - englanti - NLM (National Library of Medicine)

horizon pharma inc. - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - ergotamine tartrate 2 mg - ergotamine tartrate and caffeine indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia”. coadministration of ergotamine with potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (see precautions: drug interactions), with some cases resulting in amputation. there have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when ergotamine tartrate and caffeine was coadministered, at least one resulting in death. because of the increased risk for ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drugs and other potent inhibitors of cyp 3a4 (e.g., ketoconazole, itraconazole) (see warnings: cyp 3a4 inhibitors ). ergotamine tartrate and caffeine may cause fetal harm when administered to preg

Yhdysvallat - englanti - NLM (National Library of Medicine)

kaiser foundation hospitals - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t) - ergotamine tartrate 1 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

sagent pharmaceuticals - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate injection is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp 3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (see warnings: cyp 3a4 inhibitors ). dihydroergotamine mesylate should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm including prinzmetal's variant angina. (see warnings .) becaus

Belgia - englanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amdipharm ltd. - ergotamine tartrate 1 mg; caffeine 100 mg - tablet - 1 mg - 100 mg - ergotamine tartrate 1 mg; caffeine 100 mg - ergotamine, combinations excl. psycholeptics; n02ca72 ergotamine, combinations with psycholeptics

Yhdysvallat - englanti - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp 3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (see warnings: cyp 3a4 inhibitors ). dihydroergotamine mesylate nasal spray should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms

Yhdysvallat - englanti - NLM (National Library of Medicine)

cipla usa inc. - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp 3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (see warnings: cyp 3a4 inhibitors) . dihydroergotamine mesylate nasal spray should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm including prinzmetal's variant angina (see warnings). because dihydroergotamine mesylate nasal spray may increase blood pressure, it should not be given to patients with uncontrolled hypertension. dihydroergotamine mesylate nasal spray , 5-ht1 agonists (e.g., sumatriptan), ergotamine-containing or ergot-type medications or methysergide should not be used within 24 hours of each other. dihydroergotamine mesylate nasal spray should not be administered to patients with hemiplegic or basilar migraine. in addition to those conditions mentioned above, dihydroergotamine mesylate nasal spray is also contraindicated in patients with known peripheral arterial disease, sepsis, following vascular surgery, and severely impaired hepatic or renal function. dihydroergotamine mesylate nasal spray is contraindicated in patients who have previously shown hypersensitivity to ergot alkaloids. dihydroergotamine mesylate should not be used with peripheral and central vasoconstrictors because the combination may result in additive or synergistic elevation of blood pressure. currently available data have not demonstrated drug abuse or psychological dependence with dihydroergotamine. however, cases of drug abuse and psychological dependence in patients on other forms of ergot therapy have been reported. thus, due to the chronicity of vascular headaches, it is imperative that patients be advised not to exceed recommended dosages.

Yhdysvallat - englanti - NLM (National Library of Medicine)

exelan pharmaceuticals, inc. - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp 3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (see warnings: cyp 3a4 inhibitors) . dihydroergotamine mesylate nasal spray should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or